<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8861271</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">35211524</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">8861271</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3389/fcvm.2022.806822</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Variable</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>The whole cohort</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Male gender [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">168 (78.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">50.5 ± 11.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">153 (71.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">4 (1.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Marfan syndrome [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">7 (3.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bicuspid aortic valve [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">2 (0.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Coronary heart disease [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">30 (14.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiac valve surgery [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">3 (1.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thoracic endovascular repair [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Percutaneous coronary intervention [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative renal injury [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">39 (18.1)</td></tr></tbody></table><table-wrap-foot><p><italic>Preoperative renal injury was defined with a creatinine clearance rate &lt; 50 ml/min</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Variable</th><th valign="top" align="center">The whole cohort</th></tr></thead><tbody><tr><td valign="top" align="left">Male gender [n (%)]</td><td valign="top" align="center">168 (78.1)</td></tr><tr><td valign="top" align="left">Age (years)</td><td valign="top" align="center">50.5 ± 11.5</td></tr><tr><td valign="top" align="left">Hypertension [n (%)]</td><td valign="top" align="center">153 (71.2)</td></tr><tr><td valign="top" align="left">Diabetes [n (%)]</td><td valign="top" align="center">4 (1.9)</td></tr><tr><td valign="top" align="left">Marfan syndrome [n (%)]</td><td valign="top" align="center">7 (3.3)</td></tr><tr><td valign="top" align="left">Bicuspid aortic valve [n (%)]</td><td valign="top" align="center">2 (0.9)</td></tr><tr><td valign="top" align="left">Coronary heart disease [n (%)]</td><td valign="top" align="center">30 (14.0)</td></tr><tr><td valign="top" align="left">Cardiac valve surgery [n (%)]</td><td valign="top" align="center">3 (1.4)</td></tr><tr><td valign="top" align="left">Thoracic endovascular repair [n (%)]</td><td valign="top" align="center">5 (2.3)</td></tr><tr><td valign="top" align="left">Percutaneous coronary intervention [n (%)]</td><td valign="top" align="center">5 (2.3)</td></tr><tr><td valign="top" align="left">Preoperative renal injury [n (%)]</td><td valign="top" align="center">39 (18.1)</td></tr></tbody></table></div>Preoperative renal injury was defined with a creatinine clearance rate &lt; 50 ml/min.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2</table-label><table-caption>Operative characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T2"><label>Table 2</label><caption><p>Operative characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Variable</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>The whole cohort</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Concomitant procedure</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aortic sinus/valve plasty [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">70 (32.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Uni-Yacoub procedure [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">25 (11.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bentall/David procedure [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">22 (10.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wheat procedure [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CABG [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">20 (9.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>CPB characteristic</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nasopharyngeal temperature (°C)</td><td valign="top" align="center" rowspan="1" colspan="1">30.3 ± 0.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rectal temperature (°C)</td><td valign="top" align="center" rowspan="1" colspan="1">31.4 ± 0.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CPB time (min)</td><td valign="top" align="center" rowspan="1" colspan="1">139.7 ± 52.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cross-clamping time (min)</td><td valign="top" align="center" rowspan="1" colspan="1">55.6 ± 27.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LCCA cross-clamping time (min)</td><td valign="top" align="center" rowspan="1" colspan="1">10.3 ± 2.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACP/LBA time (min)</td><td valign="top" align="center" rowspan="1" colspan="1">14.1 ± 3.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Flow rate during LBA (L/m<sup>2</sup>/min)</td><td valign="top" align="center" rowspan="1" colspan="1">1.1 ± 0.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pressure of LCCA (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">70.2 ± 8.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Operation time (h)</td><td valign="top" align="center" rowspan="1" colspan="1">6.0 ± 1.7</td></tr></tbody></table><table-wrap-foot><p><italic>CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; LCCA, left common carotid artery; ACP, antegrade cerebral perfusion; LBA, lower body arrest</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Operative characteristics of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Variable</th><th valign="top" align="center">The whole cohort</th></tr></thead><tbody><tr><td valign="top" align="left">Concomitant procedure</td></tr><tr><td valign="top" align="left">Aortic sinus/valve plasty [n (%)]</td><td valign="top" align="center">70 (32.6)</td></tr><tr><td valign="top" align="left">Uni-Yacoub procedure [n (%)]</td><td valign="top" align="center">25 (11.6)</td></tr><tr><td valign="top" align="left">Bentall/David procedure [n (%)]</td><td valign="top" align="center">22 (10.2)</td></tr><tr><td valign="top" align="left">Wheat procedure [n (%)]</td><td valign="top" align="center">5 (2.3)</td></tr><tr><td valign="top" align="left">CABG [n (%)]</td><td valign="top" align="center">20 (9.3)</td></tr><tr><td valign="top" align="left">CPB characteristic</td></tr><tr><td valign="top" align="left">Nasopharyngeal temperature (°C)</td><td valign="top" align="center">30.3 ± 0.9</td></tr><tr><td valign="top" align="left">Rectal temperature (°C)</td><td valign="top" align="center">31.4 ± 0.9</td></tr><tr><td valign="top" align="left">CPB time (min)</td><td valign="top" align="center">139.7 ± 52.3</td></tr><tr><td valign="top" align="left">Cross-clamping time (min)</td><td valign="top" align="center">55.6 ± 27.4</td></tr><tr><td valign="top" align="left">LCCA cross-clamping time (min)</td><td valign="top" align="center">10.3 ± 2.9</td></tr><tr><td valign="top" align="left">ACP/LBA time (min)</td><td valign="top" align="center">14.1 ± 3.1</td></tr><tr><td valign="top" align="left">Flow rate during LBA (L/m2/min)</td><td valign="top" align="center">1.1 ± 0.2</td></tr><tr><td valign="top" align="left">Pressure of LCCA (mmHg)</td><td valign="top" align="center">70.2 ± 8.0</td></tr><tr><td valign="top" align="left">Operation time (h)</td><td valign="top" align="center">6.0 ± 1.7</td></tr></tbody></table></div>CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; LCCA, left common carotid artery; ACP, antegrade cerebral perfusion; LBA, lower body arrest.</transformed-table></extracted-table><extracted-table><table-id>T3</table-id><table-label>Table 3</table-label><table-caption>Operative outcomes of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T3"><label>Table 3</label><caption><p>Operative outcomes of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Variable</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>The whole cohort</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Awaken time (h)</td><td valign="top" align="center" rowspan="1" colspan="1">8.0 (4.0-18.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MVS (h)</td><td valign="top" align="center" rowspan="1" colspan="1">40.0 (20.0-68.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICU stay (days)</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (2.0-7.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of hospitalization (days)</td><td valign="top" align="center" rowspan="1" colspan="1">16.0 (13.0-21.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RBC transfusion (u)<xref rid="TN1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (1.5-8.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FFP transfusion (ml)<xref rid="TN1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">200.0 (0.0-550.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Drainage in 24 h (ml)</td><td valign="top" align="center" rowspan="1" colspan="1">640.0 (470.0-940.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiac enzyme CK-MB (NUML)</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 (1.7-6.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiac enzyme TnI (NUML)</td><td valign="top" align="center" rowspan="1" colspan="1">9.1 (3.5-19.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperative acute kidney injury [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">88 (40.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Renal injury requiring dialysis [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">21 (9.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stroke [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">9 (4.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Paraplegia [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperative 30-day death [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">21 (9.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Follow-up time (months)</td><td valign="top" align="center" rowspan="1" colspan="1">19.9 ± 13.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Follow-up rate (%)</td><td valign="top" align="center" rowspan="1" colspan="1">99% (192/194)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Late death [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">16 (8.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Reoperation [<italic>n</italic> (%)]</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.5)</td></tr></tbody></table><table-wrap-foot><p><italic>MVS, mechanical ventilation support; ICU, intensive care unit; RBC, red blood cells; FFP, fresh frozen plasma</italic>.</p><fn id="TN1"><label>a</label><p><italic>During surgery and the first 24 h after surgery. NUML, multiples the upper normal limit</italic>.</p></fn><p><italic>Postoperative Renal injury was defined using the Kidney Disease Improving Global Outcomes criteria (divide into three groups)</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Operative outcomes of 215 consecutive patients with ADIAD who underwent treatment using the Brain-Heart-first strategy.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Variable</th><th valign="top" align="center">The whole cohort</th></tr></thead><tbody><tr><td valign="top" align="left">Awaken time (h)</td><td valign="top" align="center">8.0 (4.0-18.0)</td></tr><tr><td valign="top" align="left">MVS (h)</td><td valign="top" align="center">40.0 (20.0-68.0)</td></tr><tr><td valign="top" align="left">ICU stay (days)</td><td valign="top" align="center">4.0 (2.0-7.0)</td></tr><tr><td valign="top" align="left">Duration of hospitalization (days)</td><td valign="top" align="center">16.0 (13.0-21.0)</td></tr><tr><td valign="top" align="left">RBC transfusion (u)???</td><td valign="top" align="center">4.0 (1.5-8.0)</td></tr><tr><td valign="top" align="left">FFP transfusion (ml)???</td><td valign="top" align="center">200.0 (0.0-550.0)</td></tr><tr><td valign="top" align="left">Drainage in 24 h (ml)</td><td valign="top" align="center">640.0 (470.0-940.0)</td></tr><tr><td valign="top" align="left">Cardiac enzyme CK-MB (NUML)</td><td valign="top" align="center">3.5 (1.7-6.2)</td></tr><tr><td valign="top" align="left">Cardiac enzyme TnI (NUML)</td><td valign="top" align="center">9.1 (3.5-19.5)</td></tr><tr><td valign="top" align="left">Postoperative acute kidney injury [n (%)]</td><td valign="top" align="center">88 (40.9)</td></tr><tr><td valign="top" align="left">Renal injury requiring dialysis [n (%)]</td><td valign="top" align="center">21 (9.8)</td></tr><tr><td valign="top" align="left">Stroke [n (%)]</td><td valign="top" align="center">9 (4.2)</td></tr><tr><td valign="top" align="left">Paraplegia [n (%)]</td><td valign="top" align="center">1 (0.5)</td></tr><tr><td valign="top" align="left">Postoperative 30-day death [n (%)]</td><td valign="top" align="center">21 (9.8)</td></tr><tr><td valign="top" align="left">Follow-up time (months)</td><td valign="top" align="center">19.9 ± 13.2</td></tr><tr><td valign="top" align="left">Follow-up rate (%)</td><td valign="top" align="center">99% (192/194)</td></tr><tr><td valign="top" align="left">Late death [n (%)]</td><td valign="top" align="center">16 (8.3)</td></tr><tr><td valign="top" align="left">Reoperation [n (%)]</td><td valign="top" align="center">1 (0.5)</td></tr></tbody></table></div>MVS, mechanical ventilation support; ICU, intensive care unit; RBC, red blood cells; FFP, fresh frozen plasma.aDuring surgery and the first 24 h after surgery. NUML, multiples the upper normal limit.Postoperative Renal injury was defined using the Kidney Disease Improving Global Outcomes criteria (divide into three groups).</transformed-table></extracted-table><extracted-table><table-id>T4</table-id><table-label>Table 4</table-label><table-caption>Patient characteristics categorized by KDIGO criteria.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T4"><label>Table 4</label><caption><p>Patient characteristics categorized by KDIGO criteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Patient population (<italic>n</italic>)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>No postoperative AKI [<italic>n</italic> (%)]</bold></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="3" rowspan="1"><bold>Postoperative AKI [</bold><italic><bold>n</bold></italic><bold>(%)]</bold></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Stage 1</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Stage 2</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Stage 3</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Whole cohort (215)</td><td valign="top" align="center" rowspan="1" colspan="1">127 (59.1)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (19.1)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (7.0)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (14.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Patients with preoperative renal injury (39)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (51.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (33.3)</td></tr></tbody></table><table-wrap-foot><p><italic>KDIGO, Kidney Disease Improving Global Outcomes; AKI, Acute Kidney Injury</italic>.</p><p><italic>Preoperative renal injury was defined creatinine clearance rate &lt; 50 ml/min</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient characteristics categorized by KDIGO criteria.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Patient population (n)</th><th valign="top" align="center">No postoperative AKI [n (%)]</th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="3">Postoperative AKI [n(%)]</th></tr><tr><th/><th/><th valign="top" align="center">Stage 1</th><th valign="top" align="center">Stage 2</th><th valign="top" align="center">Stage 3</th></tr></thead><tbody><tr><td valign="top" align="left">Whole cohort (215)</td><td valign="top" align="center">127 (59.1)</td><td valign="top" align="center">41 (19.1)</td><td valign="top" align="center">15 (7.0)</td><td valign="top" align="center">32 (14.9)</td></tr><tr><td valign="top" align="left">Patients with preoperative renal injury (39)</td><td valign="top" align="center">20 (51.3)</td><td valign="top" align="center">3 (7.7)</td><td valign="top" align="center">3 (7.7)</td><td valign="top" align="center">13 (33.3)</td></tr></tbody></table></div>KDIGO, Kidney Disease Improving Global Outcomes; AKI, Acute Kidney Injury.Preoperative renal injury was defined creatinine clearance rate &lt; 50 ml/min.</transformed-table></extracted-table></extracted-tables-set>